LEUKEMIA AND VEGF

Role of angiogenesis in leukemia

Coordinatore	Ospedale San Raffaele    more  Organization address address: Via Olgettina 60 city: Milano postcode: 20132 contact info Titolo: Dr. Nome: Maria Rosa Cognome: Pedrazzi Email: send email Telefono: 390226000000 Fax: 390226000000
Nazionalità Coordinatore	Italy [IT]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-4-3-IRG
Funding Scheme	MC-IRG
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-01-01   -   2012-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Ospedale San Raffaele  Organization address address: Via Olgettina 60 city: Milano postcode: 20132 contact info Titolo: Dr. Nome: Maria Rosa Cognome: Pedrazzi Email: send email Telefono: 390226000000 Fax: 390226000000	IT (Milano)	coordinator	100˙000.00
2	FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR  Organization address address: Via Olgettina 60 city: MILANO postcode: 20132 contact info Titolo: Dr. Nome: Maria Rosa Cognome: Pedrazzi Email: send email Telefono: +39 02 2643 4845 Fax: +39 02 2643 4717	IT (MILANO)	participant	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Our interest is to understand the role of VEGF expression and angiogenesis in leukemogenesis. Recently, emerging data is suggesting that in addition to promoting the growth and metastatic spread of solid tumors, angiogenesis may play an important role also in the pathophysiology of hematological malignancies. Clinical studies indicate that leukemia patients express high levels of pro-angiogenic factors such as VEGF and have increased angiogenesis in the bone marrow. However, these findings are mostly correlative and genetic proof that VEGF expression and angiogenesis support leukemogenesis is still lacking. Furthermore, the molecular mechanisms leading to high VEGF production in leukemia have not been elucidated. The transcription factor HIF-1a is the main positive regulator of VEGF expression. We therefore hypothesize that HIF-1a upregulation may cause high VEGF expression in leukemic blasts and propose to: 1) Elucidate the cause of VEGF expression in leukemic cells; 2) Study the effect of HIF-1a and VEGF overexpression on normal hematopoiesis; 3) Study the effect of HIF-1a and VEGF overexpression on leukemia onset and progression. We plan to achieve these objectives by an inter-disciplinary approach consisting of the analysis of in vitro experiments, in vivo data and clinical data. The expression of HIF-1a will be analyzed in leukemia clinical specimens and cell lines in correlation with VEGF levels, angiogenesis and disease progression. In parallel, in vivo studies in mice will address whether overexpression of HIF-1α or VEGF perturbs normal hematopoiesis and promotes leukemogenesis. These mouse models will be instrumental to test the efficacy of anti-angiogenesis and anti-Hif-1α inhibitors in the future. Funding of this proposal will foster the European reintegration of a talented scientist with extensive training in the United States while also strengthening the cooperation of European institutions with prominent research centers in the United States.'

Introduzione (Teaser)

Hypoxia or insufficient oxygen triggers the development of solid tumours. Studies by an EU-funded project have demonstrated that hypoxia-inducible factors (HIFs) play a major role in the progression of leukaemia.